Entera Bio Ltd. Q4 FY2020 earnings call

• Spiros Jamas highlighted key milestones including positive Phase 2 trial data for EB613, such as the significant increase in P1NP biomarker in the 2.5 milligram dose group of the EB613 Phase 2 trial. • EB612 Phase 2 data was published in The Journal of Bone and Mineral Research, showing a statistically significant decline in supplemental calcium usage. • Progress in the collaboration with Amgen, with preclinical studies on Amgen's drug using Entera's platform. • Ongoing business development efforts to leverage the oral delivery platform with other companies. • Current cash position is sufficient to fund operations into the second quarter of 2022.

Revenues for the year ended December 31, 2020 were $365,000, attributable to R&D services provided to Amgen. Cost of revenues for the same period were $209,000. Total operating expenses were $11.3 million, with $6.4 million in research and development expenses and $4.9 million in general and administrative expenses.

• Expected 2021 operating loss to be between $11 million and $12 million, subject to product development timing and COVID-19 impacts. • Current cash position is believed to fund operations into the second quarter of 2022.

• Developments related to the COVID-19 pandemic continue to evolve and may impact operations, as detailed in SEC filings.

Q: Jason McCarthy asked about the ratio of P1NP and CTX and comparison to other osteo drugs.

A: Spiros Jamas, Phillip Schwartz, and Art Santora discussed P1NP relating to bone formation, CTX to resorption, and the regulatory pathway for approval.

Q: Calvin Hori asked about shares issued from the ATM.

A: Jon Lieber provided information on share counts but did not specify the exact number of shares sold from the ATM.